Floatz logo

6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)

Psychotic Disorder

Seattle Institute for Biomedical and Clinical ResearchSmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

37 Active assets in the Psychotic Disorder cohort.

Asset / SponsorPhaseRating
Olanzapine
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Risperdal
Northwell Health
Phase 4BBB
Paliperidone Palmitate 3-Month Formulation
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Phase 4BBB
Haloperidol
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 4BBB
Asenapine
Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Phase 4BBB

View all 50 →

Same molecule, other indications

6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) is also rated in:

Alzheimer diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
Lewy body dementiaDormant
BB
Indicative ·
71 / 100
View asset →
schizoaffective disorderDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →